Patient perceptions and preferences of biologic therapies in SLE

被引:6
作者
Lim, S. Sam [1 ,2 ]
Kan, Hong [3 ]
Pobiner, Bonnie F. [4 ]
Bao, Gaobin [1 ]
Drenkard, Cristina [1 ,2 ]
机构
[1] Emory Univ, Sch Med, Dept Med, Div Rheumatol, Atlanta, GA 30322 USA
[2] Emory Univ, Sch Publ Hlth, Dept Epidemiol, Atlanta, GA 30322 USA
[3] Johns Hopkins Univ, Baltimore, MD USA
[4] GlaxoSmithKline USA, Res Triangle Pk, NC USA
关键词
SYSTEMIC-LUPUS-ERYTHEMATOSUS; ACTIVITY QUESTIONNAIRE; COHORT LUMINA; BRIEF INDEX; DAMAGE; US; PREVALENCE; PREDICTORS; DISEASE; VALIDATION;
D O I
10.1136/lupus-2019-000322
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective To evaluate patient perceptions of biologic therapies from a large, population-based cohort of patients with SLE with significant numbers of blacks and whites and across the full spectrum of socioeconomic strata and disease severity. Methods This was a cross-sectional study of validated patients with SLE enrolled in the Georgians Organized Against Lupus Cohort between September 2014 and August 2015. The survey instrument was developed ad hoc by the authors and contained an introduction on biologics. Results A total of 676 participants were on average 48.4 years old with 15.9 years of disease; 93.2% were female and 80.6% were black; 34.2% had private health insurance and 9.8% had no insurance; and 26.8% and 27.5% had Medicare or Medicaid, respectively. Of all respondents, 30.8% had heard of biologics, with a significant difference between blacks and whites (25.2% vs 53.4%, respectively). There were no significant differences, however, between blacks and whites with respect to ever having been on biologics (7.6% and 11.5%, respectively) or where they got their information about biologics. Out of 202 individuals who had heard of biologics, 102 (51.3%) were familiar with potential benefits or side effects, and most (n=129, 66.5%) had a neutral perception to risks associated with biologic use. There was no perception of biologics working differently between races/ethnicities. More (n=76, 62.8%) blacks preferred intravenous over subcutaneous modalities compared with whites (n=12, 37.5%) but were not as willing to pay as much out of pocket for it. Individuals with Medicare were significantly more likely to have been on biologics. Conclusions There are important similarities and differences between blacks and whites with lupus with respect to their perceptions of biologic therapies and their impact. There are opportunities to increase patient exposure to information about biologics and improve their understanding in order for them to make the best informed decision possible.
引用
收藏
页数:10
相关论文
共 29 条
[1]   Systemic lupus erythematosus in a multiethnic lupus cohort (LUMINA).: XVII.: Predictors of self-reported health-related quality of life early in the disease course [J].
Alarcón, GS ;
McGwin, G ;
Uribe, A ;
Friedman, AW ;
Roseman, JM ;
Fessler, BJ ;
Bastian, HM ;
Baethge, BA ;
Vilá, LM ;
Reveille, JD .
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2004, 51 (03) :465-474
[2]   Systemic lupus erythematosus in three ethnic groups.: XIX.: Natural history of the accrual of the American College of Rheumatology criteria prior to the occurrence of Criteria diagnosis [J].
Alarcón, GS ;
McGwin, G ;
Roseman, JM ;
Uribe, A ;
Fessler, BJ ;
Bastian, HM ;
Friedman, AW ;
Baethge, B ;
Vilá, LM ;
Reveille, JD .
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2004, 51 (04) :609-615
[3]   Biologic therapies in systemic lupus erythematosus [J].
Bernal, Christine B. ;
Zamora, Leonid D. ;
Navarra, Sandra V. .
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2015, 18 (02) :146-153
[4]   Sociodemographic associations with early disease damage in patients with systemic lupus erythematosus [J].
Cooper, Glinda S. ;
Treadwell, Edward L. ;
Clair, E. William St. ;
Gilkeson, Gary S. ;
Dooley, Mary Anne .
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2007, 57 (06) :993-999
[5]   Differences by race, sex and age in the clinical and immunologic features of recently diagnosed systemic lupus erythematosus patients in the southeastern United States [J].
Cooper, GS ;
Parks, CG ;
Treadwell, EL ;
St Clair, EW ;
Gilkeson, GS ;
Cohen, PL ;
Roubey, RAS ;
Dooley, MA .
LUPUS, 2002, 11 (03) :161-167
[6]   Trends in the Incidence, Demographics, and Outcomes of End-Stage Renal Disease Due to Lupus Nephritis in the US From 1995 to 2006 [J].
Costenbader, Karen H. ;
Desai, Amrita ;
Alarcon, Graciela S. ;
Hiraki, Linda T. ;
Shaykevich, Tamara ;
Brookhart, M. Alan ;
Massarotti, Elena ;
Lu, Bing ;
Solomon, Daniel H. ;
Winkelmayer, Wolfgang C. .
ARTHRITIS AND RHEUMATISM, 2011, 63 (06) :1681-1688
[7]  
D'Cruz D., 2019, Lupus Sci Med, V6, pA149, DOI DOI 10.1002/art.30613
[8]   Long-term prognosis and causes of death in systemic lupus erythematosus [J].
Doria, Andrea ;
Iaccarino, Luca ;
Ghirardello, Anna ;
Zampieri, Sandra ;
Arienti, Silvia ;
Sarzi-Puttini, Piercarlo ;
Atzeni, Fabiola ;
Piccoli, Antonio ;
Todesco, Silvano .
AMERICAN JOURNAL OF MEDICINE, 2006, 119 (08) :700-706
[9]   Validity of a Self-Administered Version of the Brief Index of Lupus Damage in a Predominantly African American Systemic Lupus Erythematosus Cohort [J].
Drenkard, C. ;
Yazdany, J. ;
Trupin, L. ;
Katz, P. P. ;
Dunlop-Thomas, C. ;
Bao, G. ;
Lim, S. S. .
ARTHRITIS CARE & RESEARCH, 2014, 66 (06) :888-896
[10]   Systemic lupus erythematosus in a multiethnic US cohort XLIII.: The significance of thrombocytopenia as a prognostic factor [J].
Fernandez, Monica ;
Alarcon, Graciela S. ;
Apte, Mandar ;
Andrade, Rosa M. ;
Vila, Luis M. ;
Reveille, John D. .
ARTHRITIS AND RHEUMATISM, 2007, 56 (02) :614-621